AVEO Pharmaceuticals Inc (NASDAQ:AVEO)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - AVEO

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - AVEO

  • Market Cap$241.710m
  • SymbolNASDAQ:AVEO
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINUS0535883070

Company Profile

AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America. Tivozanib is approved in the European Union as well as Norway and Iceland for the first-line treatment of adult patients with RCC.AVEO Pharmaceuticals Inc is a biopharmaceutical company focused on discovering, developing and commercializing novel cancer therapeutics. The firm offers products such as Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353.

Latest AVEO news

Currently there for this company. Visit our news hub for other news .